Wenbin Jiang - Jul 22, 2021 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: President and CEO, Director
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Stock symbol: CTKB
Transactions as of: Jul 22, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/27/2021, 08:55 PM
Next filing: Feb 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Conversion of derivative security		+2.67M			2.67M	Jul 22, 2021	See footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTKB	Series A Preferred Stock	Conversion of derivative security	$0	-2.67M	-100%	$0.00^*	0	Jul 22, 2021	Common Stock	2.67M		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2	These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any.